HSR Waiting Period Expires for Eli Lilly's $2.8B AtaiBeckley Acquisition
ATAI has more than doubled off its 52-week low of $3.265.
Summary
The Hart-Scott-Rodino waiting period for Eli Lilly's acquisition of AtaiBeckley expired on August 28, 2026, clearing a key U.S. antitrust hurdle. The UK Competition Authority also confirmed no further questions as of August 21. These clearances remove regulatory uncertainty ahead of the September 8 shareholder vote on the $6.75 per share cash plus CVR deal. The stock trades near its 52-week high, reflecting market confidence in deal completion.
At the time of this announcement, ATAI was trading at $7.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $3.27 to $7.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.